Abcam, ab273711, Human TMEM106B knockout A549 cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
TMEM106B KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. Knockout achieved by CRISPR/Cas9 X = 1 bp insertion Frameshift: 100%. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Form:LiquidSee storage information,
Knockout validation:Next Generation Sequencing,
Mutation description:Knockout achieved by CRISPR/Cas9 X = 1 bp insertion Frameshift: 100%,
Disease:Carcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-TMEM106B, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TMEM106B also known as transmembrane protein 106B is a type II single-pass transmembrane protein with a molecular mass of approximately 33 kDa. It is expressed in specific regions of the brain as well as in other tissue types such as the lungs and immune system cells. Its expression levels are especially elevated in microglia and oligodendrocytes which are brain cells that play important roles in immune response and myelination respectively. Structurally TMEM106B contains a transmembrane domain and its precise biochemical function is still under investigation though it is thought to participate in lysosomal and vesicular trafficking.
Biological function summary
TMEM106B is involved in several cellular processes impacting lysosome function and trafficking. It may become part of a protein complex that manages lysosomal positioning and pathway regulation within the cell. TMEM106B also affects cellular homeostasis and protein degradation which suggests a role in maintaining the proper balance of proteins and lipids within lysosomes. Alteration in TMEM106B expression or function can cause changes in lysosomal size and distribution indicating its role in cellular logistics.
Pathways
The TMEM106B protein becomes involved in the endolysosomal pathway and the autophagy-lysosome pathway. These pathways are critical for processing and breakdown of cellular waste and recycling of cellular components. In these pathways TMEM106B interacts with other proteins such as SORT1 (sortilin 1) and GRN (progranulin) both of which have important roles in protein sorting and trafficking. By influencing these pathways TMEM106B helps maintain cellular health and function.
TMEM106B links to neurodegenerative conditions such as frontotemporal lobar degeneration and possibly Alzheimer's disease. Mutations or abnormal expression levels of TMEM106B have been implicated in the pathogenesis and progression of these diseases. In frontotemporal lobar degeneration TMEM106B interacts with proteins like GRN where changes can lead to neurodegeneration. In Alzheimer's disease abnormal lysosomal function tied to TMEM106B may contribute to the accumulation of pathogenic proteins.